Bio-Rad Stock Rises 10.5% to $273.47
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Bio-Rad is up 10.5%, or $25.94 to $273.47.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIO
Wall Street analysts forecast BIO stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 318.220
Low
340.00
Averages
340.00
High
340.00
Current: 318.220
Low
340.00
Averages
340.00
High
340.00
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
NextEra's Acquisition of Dominion Drives Stock Surge
- Acquisition Impact: NextEra Energy's announcement of an all-stock acquisition of Dominion Energy led to a more than 9% surge in Dominion's shares, positioning the combined entity as the world's largest regulated electric utility, significantly enhancing market presence.
- Cruise Industry Recovery: Viking Holdings' stock rose nearly 2% after Wells Fargo upgraded its rating to overweight, with 2027 advanced bookings up 31% from the previous year, indicating strong demand despite concerns over the U.S.-Iran conflict.
- Stock Buyback Plan: Cognizant Technology Solutions saw its shares increase by nearly 7% after doubling its stock repurchase target to approximately $2 billion for this year, which is expected to boost investor confidence and enhance shareholder value.
- Medical Device Investment: Boston Scientific's shares rose over 3% as it announced a $2 billion accelerated stock repurchase plan and a $1.5 billion investment in MiRus, allowing it to re-enter the transcatheter aortic valve replacement market, demonstrating strategic expansion in the medical field.
See More
Major Premarket Stock Movements in Key Companies
- Regeneron Drug Trial Failure: Regeneron Pharmaceuticals saw its stock plummet over 11% after its skin cancer treatment failed to meet goals in a late-stage trial, potentially undermining investor confidence and future R&D funding.
- Macy's Stock Surge: Macy's shares jumped nearly 4% in premarket trading after a regulatory filing revealed that Berkshire Hathaway initiated a small position valued at approximately $55 million, raising speculation about investment lieutenant Ted Weschler's involvement.
- Dominion Energy Acquisition News: Dominion Energy's stock surged more than 12% following NextEra Energy's announcement of an all-stock acquisition deal, which is expected to create the world's largest regulated electric utility, significantly enhancing market presence.
- Bio Rad Laboratories Stock Spike: Bio Rad Laboratories' shares rose 13% after a Wall Street Journal report indicated that activist investor Elliott Investment Management has built a sizable stake in the company, although the exact size and Elliott's strategic vision remain undisclosed.
See More
Elliott Investment Builds Stake in Bio-Rad to Boost Stock Price
- Investor Engagement: Activist investor Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (BIO) with the intention of pushing for an increase in its underperforming stock price, indicating strong interest in the company's future performance.
- Strategic Investment Link: Elliott is also a major investor in Sartorius (SARTF), a German supplier of pharmaceutical and laboratory equipment, with Bio-Rad holding a strategic investment in Sartorius, suggesting that their business relationship may influence Bio-Rad's market performance.
- Financial Performance Decline: Bio-Rad recently lowered its 2026 revenue growth outlook to between -3% and +0.5%, reporting a first-quarter net loss of $527 million, reflecting the company's vulnerability in a changing market environment.
- Market Reaction: Bio-Rad's non-GAAP EPS of $1.89 missed expectations by $0.10, although its revenue of $592.1 million beat estimates by $3.24 million, highlighting market concerns regarding its future growth prospects.
See More
Bio-Rad Laboratories Q1 2026 Earnings Call Insights
- Middle East Impact: Bio-Rad's Q1 2026 earnings report indicates significant pressure on revenue and margins due to the ongoing Middle East conflict, with full-year revenue growth guidance adjusted to between -3% and +0.5%, highlighting the substantial external threats to the company's performance.
- Sales and Margins: The company reported net sales of approximately $592 million and a non-GAAP EPS of $1.89, while the gross margin stood at 52.3%, reflecting challenges in cost control due to unfavorable manufacturing absorption and other factors impacting profitability.
- Digital PCR Growth: Bio-Rad's ddPCR instrument revenue grew by 24% year-over-year, with the new QX700 platform driving market share gains, indicating enhanced competitiveness in the digital PCR space and potential for further market influence.
- Acquisition Strategy Shift: Management noted a strategic shift in acquisition focus from early-stage opportunities to companies with demonstrated revenue and margin profiles, targeting firms with revenues between $100 million and $500 million, reflecting a cautious approach to future growth.
See More
Bio-Rad Laboratories to Announce Q1 Earnings on April 30
- Earnings Announcement Schedule: Bio-Rad Laboratories is set to release its Q1 2023 earnings report on April 30 after market close, with consensus EPS estimates at $1.99, reflecting a 21.7% year-over-year decline, while revenue is expected to reach $588.86 million, a slight increase of 0.6% year-over-year.
- Historical Performance Review: Over the past two years, Bio-Rad has exceeded EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability in its financial performance amidst market fluctuations.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with three downward adjustments, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting a cautious market outlook on the company's future performance.
- Future Outlook: Bio-Rad has outlined a revenue growth guidance of 0.5% to 1.5% for 2026, alongside plans for margin expansion through operational improvements, demonstrating the company's proactive approach to future growth and profitability enhancement.
See More
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
NextEra's Acquisition of Dominion Drives Stock Surge
- Acquisition Impact: NextEra Energy's announcement of an all-stock acquisition of Dominion Energy led to a more than 9% surge in Dominion's shares, positioning the combined entity as the world's largest regulated electric utility, significantly enhancing market presence.
- Cruise Industry Recovery: Viking Holdings' stock rose nearly 2% after Wells Fargo upgraded its rating to overweight, with 2027 advanced bookings up 31% from the previous year, indicating strong demand despite concerns over the U.S.-Iran conflict.
- Stock Buyback Plan: Cognizant Technology Solutions saw its shares increase by nearly 7% after doubling its stock repurchase target to approximately $2 billion for this year, which is expected to boost investor confidence and enhance shareholder value.
- Medical Device Investment: Boston Scientific's shares rose over 3% as it announced a $2 billion accelerated stock repurchase plan and a $1.5 billion investment in MiRus, allowing it to re-enter the transcatheter aortic valve replacement market, demonstrating strategic expansion in the medical field.
See More
Major Premarket Stock Movements in Key Companies
- Regeneron Drug Trial Failure: Regeneron Pharmaceuticals saw its stock plummet over 11% after its skin cancer treatment failed to meet goals in a late-stage trial, potentially undermining investor confidence and future R&D funding.
- Macy's Stock Surge: Macy's shares jumped nearly 4% in premarket trading after a regulatory filing revealed that Berkshire Hathaway initiated a small position valued at approximately $55 million, raising speculation about investment lieutenant Ted Weschler's involvement.
- Dominion Energy Acquisition News: Dominion Energy's stock surged more than 12% following NextEra Energy's announcement of an all-stock acquisition deal, which is expected to create the world's largest regulated electric utility, significantly enhancing market presence.
- Bio Rad Laboratories Stock Spike: Bio Rad Laboratories' shares rose 13% after a Wall Street Journal report indicated that activist investor Elliott Investment Management has built a sizable stake in the company, although the exact size and Elliott's strategic vision remain undisclosed.
See More
Elliott Investment Builds Stake in Bio-Rad to Boost Stock Price
- Investor Engagement: Activist investor Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (BIO) with the intention of pushing for an increase in its underperforming stock price, indicating strong interest in the company's future performance.
- Strategic Investment Link: Elliott is also a major investor in Sartorius (SARTF), a German supplier of pharmaceutical and laboratory equipment, with Bio-Rad holding a strategic investment in Sartorius, suggesting that their business relationship may influence Bio-Rad's market performance.
- Financial Performance Decline: Bio-Rad recently lowered its 2026 revenue growth outlook to between -3% and +0.5%, reporting a first-quarter net loss of $527 million, reflecting the company's vulnerability in a changing market environment.
- Market Reaction: Bio-Rad's non-GAAP EPS of $1.89 missed expectations by $0.10, although its revenue of $592.1 million beat estimates by $3.24 million, highlighting market concerns regarding its future growth prospects.
See More
Bio-Rad Laboratories Q1 2026 Earnings Call Insights
- Middle East Impact: Bio-Rad's Q1 2026 earnings report indicates significant pressure on revenue and margins due to the ongoing Middle East conflict, with full-year revenue growth guidance adjusted to between -3% and +0.5%, highlighting the substantial external threats to the company's performance.
- Sales and Margins: The company reported net sales of approximately $592 million and a non-GAAP EPS of $1.89, while the gross margin stood at 52.3%, reflecting challenges in cost control due to unfavorable manufacturing absorption and other factors impacting profitability.
- Digital PCR Growth: Bio-Rad's ddPCR instrument revenue grew by 24% year-over-year, with the new QX700 platform driving market share gains, indicating enhanced competitiveness in the digital PCR space and potential for further market influence.
- Acquisition Strategy Shift: Management noted a strategic shift in acquisition focus from early-stage opportunities to companies with demonstrated revenue and margin profiles, targeting firms with revenues between $100 million and $500 million, reflecting a cautious approach to future growth.
See More
Bio-Rad Laboratories to Announce Q1 Earnings on April 30
- Earnings Announcement Schedule: Bio-Rad Laboratories is set to release its Q1 2023 earnings report on April 30 after market close, with consensus EPS estimates at $1.99, reflecting a 21.7% year-over-year decline, while revenue is expected to reach $588.86 million, a slight increase of 0.6% year-over-year.
- Historical Performance Review: Over the past two years, Bio-Rad has exceeded EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability in its financial performance amidst market fluctuations.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with three downward adjustments, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting a cautious market outlook on the company's future performance.
- Future Outlook: Bio-Rad has outlined a revenue growth guidance of 0.5% to 1.5% for 2026, alongside plans for margin expansion through operational improvements, demonstrating the company's proactive approach to future growth and profitability enhancement.
See More
